Business
Appointment of Joint Broker
Appointment of Joint Broker.
About this update from Ip Group Plc
[{"type":"text","content":"\n \nRNS Number : 2449S IP Group PLC 22 June 2018 \n\n\n\n\n\nFOR RELEASE ON\n\n\n22 June 2018\n\n\n\n\n \nIP Group plc - Appointment of Joint Broker\n \nIP Group plc (LSE: IPO) (\"IP Group\" or \"the Group\" or \"the Company\"), the developer of intellectual property-based businesses, announces the appointment of Berenberg as joint broker alongside Numis Securities Limited with immediate effect. \n \nFor more information, please contact:\n \n\n\n\n\nIP Group plc\n\n\nwww.ipgroupplc.com\n\n\n\n\nAlan Aubrey, Chief Executive Officer\nGreg Smith, Chief Financial Officer\nLiz Vaughan-Adams, Communications \n\n\n+44 (0) 20 7444 0050\n\n+44 (0) 20 7444 0062/+44 (0) 7979 853802\n\n\n\n\nCharlotte Street Partners\n\n\n \n\n\n\n\nAndrew Wilson\n\n\n+44 (0) 7810 636995\n\n\n\n\nMartha Walsh\n\n\n+44 (0) 7876 245962\n\n\n\n\n \nNotes for editors\n \nAbout IP Group\n \nIP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.\n \nENDS\n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END APPEAPKAASSPEEF\n ","length":4786,"tagName":"div"}]